In the year 2000, Femarelle^® began its commercialization stage and consumers around the world have started to enjoy the benefits that it provides. In Finland, Femarelle^® is sold under the trade name Bonfemi^®.  Bonfemi^®'s uniqueness lies in its being a Selective Estrogen Receptor Modulator- a SERM. The selectivity in the estrogen receptor bondage provides both menopausal symptoms relief and bone health, without affecting the sensitive tissues in the breast and uterus.  Thus, Bonfemi^® provides a safe and effective solution for the management of menopause.  The scientific activity surrounding Bonfemi^® provides published studies in leading scientific journals worldwide, as well as international recognition and acceptance by the medical community both in practice and in leading medical conventions. The research process continues and new studies are constantly being conducted in order to provide comprehensive data proving both the efficacy and safety of use of the product.